ARKG241227P19500
- 0.00
- 0.000.00%
ARK Genomic Revolution ETF Newsroom
2024's 'Biggest Loses' That Could See Reversal in 2025
SA Asks: Which Big Pharmas Are Likely to Announce Big M&A Deals?
JMP Securities Reiterates Market Outperform on CRISPR Therapeutics, Maintains $86 Price Target
Trending Industry Today: ARK Genomic Revolution ETF Leads Losses In ARK ETFs Stocks
Adaptive Biotechnologies Analyst Ratings
Twist Bioscience Analyst Ratings
Natera Analyst Ratings
Natera Announces Enrollment Of First Patients In SAGITTARIUS A Randomized Phase III Clinical Trial In Colon Cancer; ~700-900 Patients Expected To Be Enrolled Across More Than 20 Sites
Cathie Wood's Ark Invest Trims Tesla Exposure Amid Searing Rally, Sells $21.8M Worth Of Stock — Bets On This AI Medical Company
Editas Cut to Equal Weight by Wells Fargo Over Reni-cel Positioning
Needham Reiterates Buy on Recursion Pharmaceuticals, Maintains $11 Price Target
Recursion Pharmaceuticals Analyst Ratings
CareDx Announced That CareDx Will Partner With TC BioPharm To Perform Pharmacokinetic Analysis Using Its AlloCell Solution In The Achieve Clinical Trial
Top 3 Health Care Stocks That May Collapse This Quarter
10 Health Care Stocks With Whale Alerts In Today's Session
What's Going On With Recursion Pharmaceuticals Stock?
CRISPR Therapeutics Analyst Ratings
Beam Therapeutics Analyst Ratings
Vertex Reports Positive Long-term Data for Casgevy
CRISPR Therapeutics Highlights CTX112 Data At ASH 2024, Showcasing Potential Clinical Benefits In R/R CD19-Positive B-Cell Malignancies; Receives FDA RMAT Designation For Follicular And Marginal Zone Lymphomas, With Phase 1 Trial Expanding Into...